Nanobiotix S.A. ADR (NBTX) Stock Price, Quote & News

Company Profile

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 1 40 26 04 70

Fax: 33 1 40 26 04 44

Website: www.nanobiotix.com

Address:

60 rue de Wattignies, Paris, France

HayesPivot Sep. 18 at 6:42 PM

$NBTX I want leaders not laggards NXXT checks innovation optionality and catalysts patience and adds win when news cycle turns

0 · Reply

RiverPeakEquity Sep. 18 at 5:16 PM

$NBTX NXXT insiders loaded heavy, float tight, bids stepping, feels like staircase up not an elevator down 🚀

0 · Reply

Joby099 Sep. 18 at 5:11 PM

$ETNB $PBM $AQB $NBTX $IHT

0 · Reply

notreload_ai Sep. 18 at 3:31 PM

$NBTX JNJ-1900 offers new hope for advanced melanoma patients whose cancer progressed after many treatments, including anti-PD-1. Injected into tumors, activated by radiation, then combined with anti-PD-1, it shows promising early safety and efficacy signals, potentially boosting the immune system. https://notreload.xyz/nanobiotix-skin-cancer-therapy-positive-early-stage-data/

0 · Reply

Malayah_Pollard_71 Sep. 18 at 2:28 PM

$NBTX NXXT smart money accumulates quiet before headlines the bid feels sticky dips keep getting bought tells me someone knows

0 · Reply

jjstock1 Sep. 18 at 2:19 PM

$NVDA $SPY……. $NBTX its going to fly 19 ?

0 · Reply

topstockalerts Sep. 18 at 1:55 PM

Top Gainers PT2 $AERT $INTC $PESI $NBTX $ORBS

0 · Reply

OpenOutcrier Sep. 18 at 12:28 PM

$NBTX (+22.5% pre) NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1 https://ooc.bz/l/77684

0 · Reply

topstockalerts Sep. 18 at 12:05 PM

$NBTX what’s your target for today?

1 · Reply

Zohan_69 Sep. 18 at 11:55 AM

$APVO 👉🏼 👀 $PBM 🔥 $DVLT $NBTX $RMCF

0 · Reply

Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday

Sep 18, 2025, 1:56 PM EDT - 6 hours ago

Nanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull Case

Sep 18, 2025, 10:13 AM EDT - 9 hours ago

Nanobiotix S.A. - Special Call

Sep 17, 2025, 4:15 PM EDT - 1 day ago

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

Sep 2, 2025, 4:15 PM EDT - 16 days ago

Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Jul 7, 2025, 4:15 PM EDT - 2 months ago

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

May 28, 2025, 2:00 AM EDT - 4 months ago

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference

May 21, 2025, 4:15 PM EDT - 4 months ago

Nanobiotix Provides First Quarter 2025 Operational and Financial Update

May 12, 2025, 2:00 AM EDT - 4 months ago

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

May 5, 2025, 2:00 AM EDT - 4 months ago

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

Apr 30, 2025, 2:00 AM EDT - 5 months ago

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Apr 3, 2025, 4:24 PM EDT - 6 months ago

Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript

Apr 2, 2025, 4:15 PM EDT - 6 months ago

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

Mar 31, 2025, 2:00 AM EDT - 6 months ago

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

Mar 27, 2025, 4:15 PM EDT - 6 months ago

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

Mar 20, 2025, 4:15 PM EDT - 6 months ago

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

Mar 17, 2025, 4:15 PM EDT - 6 months ago

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

Jan 29, 2025, 4:15 PM EST - 8 months ago

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

Jan 21, 2025, 2:30 AM EST - 8 months ago

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

Dec 17, 2024, 4:15 PM EST - 9 months ago

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

Dec 9, 2024, 4:15 PM EST - 10 months ago

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

Nov 12, 2024, 2:30 AM EST - 11 months ago

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

Oct 31, 2024, 3:30 AM EDT - 11 months ago

NANOBIOTIX to Participate in Multiple Investor Conferences in November

Sep 18, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results

Sep 4, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth

Sep 3, 2024, 4:15 PM EDT - 1 year ago

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference

Jun 12, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

Jun 2, 2024, 10:00 AM EDT - 1 year ago

Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy

May 28, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call

May 23, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

May 22, 2024, 8:32 PM EDT - 1 year ago

Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript

May 22, 2024, 2:00 AM EDT - 1 year ago

NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

May 21, 2024, 4:15 PM EDT - 1 year ago

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

May 15, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

May 14, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer

Apr 27, 2024, 11:51 AM EDT - 1 year ago

Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript

Apr 24, 2024, 4:40 PM EDT - 1 year ago

NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results

Apr 17, 2024, 4:15 PM EDT - 1 year ago

NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024

Apr 2, 2024, 4:15 PM EDT - 1 year ago

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

Mar 6, 2024, 4:15 PM EST - 1 year ago

Nanobiotix to Present at Upcoming Investor Conferences in March

Jan 31, 2024, 4:15 PM EST - 1 year ago

Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference

Jan 29, 2024, 4:15 PM EST - 1 year ago

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

Nov 14, 2023, 1:01 PM EST - 2 years ago

Nanobiotix S.A. (NBTX) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 4:15 PM EST - 2 years ago

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

Nov 9, 2023, 4:15 PM EST - 2 years ago

NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023

Nov 7, 2023, 4:01 PM EST - 2 years ago

NANOBIOTIX Announces Closing of Global Offering

Nov 6, 2023, 2:00 AM EST - 2 years ago

NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M

Nov 2, 2023, 10:49 AM EDT - 2 years ago

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

Nov 1, 2023, 6:32 PM EDT - 2 years ago

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

Oct 23, 2023, 2:00 AM EDT - 2 years ago

NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

HayesPivot Sep. 18 at 6:42 PM

$NBTX I want leaders not laggards NXXT checks innovation optionality and catalysts patience and adds win when news cycle turns

0 · Reply

RiverPeakEquity Sep. 18 at 5:16 PM

$NBTX NXXT insiders loaded heavy, float tight, bids stepping, feels like staircase up not an elevator down 🚀

0 · Reply

Joby099 Sep. 18 at 5:11 PM

$ETNB $PBM $AQB $NBTX $IHT

0 · Reply

notreload_ai Sep. 18 at 3:31 PM

0 · Reply

Malayah_Pollard_71 Sep. 18 at 2:28 PM

$NBTX NXXT smart money accumulates quiet before headlines the bid feels sticky dips keep getting bought tells me someone knows

0 · Reply

jjstock1 Sep. 18 at 2:19 PM

$NVDA $SPY……. $NBTX its going to fly 19 ?

0 · Reply

topstockalerts Sep. 18 at 1:55 PM

Top Gainers PT2 $AERT $INTC $PESI $NBTX $ORBS

0 · Reply

OpenOutcrier Sep. 18 at 12:28 PM

0 · Reply

topstockalerts Sep. 18 at 12:05 PM

$NBTX what’s your target for today?

1 · Reply

Zohan_69 Sep. 18 at 11:55 AM

$APVO 👉🏼 👀 $PBM 🔥 $DVLT $NBTX $RMCF

0 · Reply

PremarketAddict Sep. 18 at 11:53 AM

PREMARKET GAINERS(PT.2) : $INTC 28.4% / 29.3 MIL VOL $ATCH 26.5% / 13.7 MIL VOL $BEEM 24% / 12.7 MIL VOL $NBTX 22% / 12.7 MIL VOL

0 · Reply

peterpancake Sep. 18 at 11:31 AM

$NBTX skin cancer affects millions of people

0 · Reply

topstockalerts Sep. 18 at 11:06 AM

Pre Market Top Gainers PT2 $DVLT $ATCH $NBTX $MLGO $AIIO

0 · Reply

jdlman Sep. 18 at 10:56 AM

$NBTX like it

0 · Reply

SmallCapAlert Sep. 18 at 10:50 AM

$INNPF Watchlist: $INNPF InnoCan Pharma. Preparing NASDAQ listing Marketcap: $38 million $NBTX Marketcap: $466 million $AKRO Marketcap: $3.41 billion $SONN Marketcap: $44 million $MEIP Marketcap: $88 million

0 · Reply

Zohan_69 Sep. 18 at 9:49 AM

$APVO 🚀 $PBM 🚀 $DVLT $NBTX $RMCF

0 · Reply